Localized Small Bowel Adenocarcinoma Management: Evidence Summary

Turpin, Anthony; El Amrani, Mehdi; Zaanan, Aziz

Type de document :

Article dans une revue scientifique: Article original

DOI :

10.3390/cancers14122892

Titre :

Localized Small Bowel Adenocarcinoma Management: Evidence Summary

Auteur(s) :

Turpin, Anthony [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
El Amrani, Mehdi [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Zaanan, Aziz [Auteur]
Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)]

Titre de la revue :

Cancers

Pagination :

2892

Éditeur :

MDPI

Date de publication :

2022-06-11

ISSN :

2072-6694

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Cancer

Résumé en anglais : [en]

Small bowel cancers are rare diseases whose prognosis is poorer than that of colon cancers. Due to disease rarity, there is little data on small bowel adenocarcinoma (SBA) treatment, and most recommendations come from ...
Lire la suite >Small bowel cancers are rare diseases whose prognosis is poorer than that of colon cancers. Due to disease rarity, there is little data on small bowel adenocarcinoma (SBA) treatment, and most recommendations come from expert agreements or analogies to the management of colon cancer. Although relatively high rates of local recurrence are observed for duodenal malignancies, distant metastatic relapse remains common and requires adjuvant systemic therapy. Given the similarities between SBA and colorectal cancer, radiotherapy and chemotherapy strategies used for the latter disease are frequently pursued for the former disease, specifically for tumors located in the duodenum. However, no previous randomized study has evaluated the benefit of adjuvant chemotherapy on the overall survival of SBA patients. Most previous studies on treatment outcomes and prognostic factors in this context were based on large international databases, such as the Surveillance, Epidemiology, and End Results or the National Cancer Database. Studies are required to establish and validate prognostic and predictive markers relevant in this context to inform the use of (neo) adjuvant treatment. Among those, deficient mismatch repair tumors represent 20% of SBAs, but their impact on chemosensitivity remains unknown. Herein, we summarize the current evidence on the management of localized SBA, including future perspectives.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :